Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer

• DOI: 10.1002/adtp.202300388
• Publication Date: 2024-03-11T11:41:24Z
• Authors: Saurabh Sharma; Rajesh Pradhan; David Lee; Mahalaxmi Sharma; Shima Zahed Nasab; Siddhanth Hejmady; Subhash Chander; Neda Mohaghegh; Surjendu Maity; Shahid Khan; Ali Khademhosseini; Amanda Kirane
• Keywords: Triple-negative breast cancer; Nanocarriers; Translational Research

Abstract Triple‐negative breast cancer develops from malignant cells within the interior lining of milk ducts or, less frequently, in stromal tissues and accounts for ≈15% all cancers. Breast is highly prevalent with overall number cases expected to reach 27.78 million by 2040, according World Health Organization. MiRNAs serve a novel role management through their ability indirectly control translation coding mRNA regulate expression specific genes, which allows it play significant therapeutics. However, inherent characteristics miRNA including rapid clearance via renal excretion, degradation nucleases plasma, additional factors limit its clinical application. To reduce these limitations, can be administered conjunction small molecules nanocarriers, then allow impart benefits inhibition epithelial–mesenchymal transitions, inhibiting tumor angiogenesis. This review highlights current application nanocarrier‐based delivery approach miRNA/siRNA triple negative treatment.